| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D489-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-472
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485 |
| filingDate |
2016-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2021-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-107921041-B |
| titleOfInvention |
A kind of Duo-like receptor 4 antagonist and its use in autoimmune liver disease |
| abstract |
The present invention relates to a new medical use of morphinane such as naltrexone, nalmefene and related derivatives thereof. The present invention relates to Dol-like receptor 4 antagonistic compounds and pharmaceutical preparations thereof, as well as their use in preventing and treating autoimmune liver diseases (including but not limited to autoimmune hepatitis). |
| priorityDate |
2015-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |